<DOC>
	<DOC>NCT01318655</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of NKTR-118 with healthy subjects.</brief_summary>
	<brief_title>Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects</brief_title>
	<detailed_description>A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of NKTR-118 following single and multiple ascending oral dose administration in healthy young and elderly Japanese subjects, and an Open Randomized, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics after single oral doses of NKTR-118 in healthy male Japanese subjects</detailed_description>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>20 Years to 45 Years, 65 Years to 80 Years Body mass index (BMI): 18 to 27 kg/m Male subjects should be willing to use barrier contraception ie, condoms, from the day of dosing until 3 months after dosing with the investigational product. Nonsmokers or exsmokers (not smoked in the past 3 months). Clinically relevant disease and/or abnormalities (past or present) Clinically relevant abnormalities in physical examinations,vital signs,clinical chemistry, hematology or urinalysis as judged by the investigator Use of any prescribed or nonprescribed medication including herbal remedies, vitamins and minerals during the two weeks prior to the first administration of investigational product</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Japan</keyword>
	<keyword>SAD</keyword>
	<keyword>MAD</keyword>
</DOC>